Literature DB >> 33630055

New hope offered to reduce GVHD.

Yi Zhang1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33630055      PMCID： PMC7907725          DOI： 10.1182/blood.2020009205

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  The retinoid X receptors and their ligands.

Authors:  Marcia I Dawson; Zebin Xia
Journal:  Biochim Biophys Acta       Date:  2011-10-01

2.  An essential role for Rxr alpha in the development of Th2 responses.

Authors:  Xin Du; Koichi Tabeta; Navjiwan Mann; Karine Crozat; Suzanne Mudd; Bruce Beutler
Journal:  Eur J Immunol       Date:  2005-12       Impact factor: 5.532

Review 3.  Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.

Authors:  Robert Zeiser; Bruce R Blazar
Journal:  N Engl J Med       Date:  2017-11-30       Impact factor: 91.245

4.  Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells.

Authors:  Shan He; Jina Wang; Koji Kato; Fang Xie; Sooryanarayana Varambally; Shin Mineishi; Rork Kuick; Kazuhiro Mochizuki; Yongnian Liu; Evelyn Nieves; Ram-Shankar Mani; Arul M Chinnaiyan; Victor E Marquez; Yi Zhang
Journal:  Blood       Date:  2011-11-23       Impact factor: 22.113

Review 5.  Treg functional stability and its responsiveness to the microenvironment.

Authors:  Joseph Barbi; Drew Pardoll; Fan Pan
Journal:  Immunol Rev       Date:  2014-05       Impact factor: 12.988

6.  Effector T cells require fatty acid metabolism during murine graft-versus-host disease.

Authors:  Craig A Byersdorfer; Victor Tkachev; Anthony W Opipari; Stefanie Goodell; Jacob Swanson; Stacy Sandquist; Gary D Glick; James L M Ferrara
Journal:  Blood       Date:  2013-09-17       Impact factor: 22.113

7.  Corruption of dendritic cell antigen presentation during acute GVHD leads to regulatory T-cell failure and chronic GVHD.

Authors:  Lucie Leveque-El Mouttie; Motoko Koyama; Laetitia Le Texier; Kate A Markey; Melody Cheong; Rachel D Kuns; Katie E Lineburg; Bianca E Teal; Kylie A Alexander; Andrew D Clouston; Bruce R Blazar; Geoffrey R Hill; Kelli P A MacDonald
Journal:  Blood       Date:  2016-06-23       Impact factor: 22.113

8.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.

Authors:  Matthias Edinger; Petra Hoffmann; Joerg Ermann; Kathryn Drago; C Garrison Fathman; Samuel Strober; Robert S Negrin
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

9.  Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production.

Authors:  Robert Zeiser; Vu H Nguyen; Andreas Beilhack; Martin Buess; Stephan Schulz; Jeanette Baker; Christopher H Contag; Robert S Negrin
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

10.  Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses.

Authors:  Govindarajan Thangavelu; Chao Wang; Michael Loschi; Asim Saha; Mark J Osborn; Scott N Furlan; Kazutoshi Aoyama; Cameron McDonald-Hyman; Ethan G Aguilar; Amanda S Janesick; Roshantha A Chandraratna; Yosef Refaeli; Angela Panoskaltsis-Mortari; Kelli P MacDonald; Geoffrey R Hill; Robert Zeiser; Ivan Maillard; Jonathan S Serody; William J Murphy; David H Munn; Bruce Blumberg; Chrysothemis Brown; Vijay Kuchroo; Leslie S Kean; Keli L Hippen; Randolph J Noelle; Bruce R Blazar
Journal:  Blood       Date:  2021-02-25       Impact factor: 25.476
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.